Gonadal Function in Children With Nephrosis Treated With Cyclophosphamide

Pennisi, Alfred J.

doi:10.1001/archpedi.1975.02120400027006

Cited by 33 publications

(7 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two of these patients had testicular RT (1200 cGy in 4 fractions). Other authors did neither observe clinically significant impairment of LC after the testicular dose of this size (Brauner et al 1983, Castillo et al 1999 (Pennisi et al 1975). All our 16 patients with LC damage had damage of germinal epithelium as well.…”

Section: Leydig Cell Damagementioning

confidence: 83%

Hypogonadism After Childhood Cancer Treatment

Zaletel¹,

Todorovski²,

Jereb³

2012

Sex Hormones

View full text Add to dashboard Cite

Section: Leydig Cell Damagementioning

confidence: 83%

Hypogonadism After Childhood Cancer Treatment

Zaletel¹,

Todorovski²,

Jereb³

2012

Sex Hormones

View full text Add to dashboard Cite

“…It is well known that prepubertal children receiving chemotherapy are more likely to maintain gonadal function than young adults. This allows for a hypothesis that inhibition of the hypothalamic-pituitary axis by GnRH-a may bring out quiescent gonads, simulating the prepubertal state, and thus rendering the gonads less susceptible to cytotoxic treatment [11,12]. Alternatively, the direct influence of GnRH-a on the ovary and reduced blood flow to the ovary may suppress ovarian function, thus rendering the gonads less susceptible to cytotoxic treatment [13].…”

Section: Discussionmentioning

confidence: 99%

The feasibility and efficacy of gonadotropin-releasing hormone agonists for prevention of chemotherapy induced ovarian failure in patient with gynecological malignancies

et al. 2014

View full text Add to dashboard Cite

ObjectiveTo assess the effects of a gonadotropin-releasing hormone agonist (GnRH-a) depot (Leuprolide acetate) in women with gynecologic cancer receiving chemotherapy while taking a continuous add-back on the prevention of premature ovarian failure.MethodsFourteen premenopausal patients with gynecological malignancies who had undergone conservation of ovaries surgery received a GnRH-a depot plus add-back until chemotherapy was completed. Four weeks thereafter, a hormonal profile (follicle stimulating hormone) was measured.ResultsThe mean follicle stimulating hormone level was 15.8 IU/L. All patients exhibited a restoration of ovarian failure during follow-up. One patient became pregnant during the follow-up period.ConclusionIn the short term, GnRH-a appears to protect ovarian function and ability to achieve pregnancy following chemotherapy. The result of our study needs further elucidation in a large randomized controlled trial.

show abstract

“…Gonadal toxic complications of cyclophosphamide treat¬ ment were first reported in patients treated in childhood for nephrotic syndrome (14)(15)(16)(17)(18). Several of these inves¬ tigations demonstrated a relationship between these toxic effects and the cumulative drug dose (16)(17)(18) and duration of therapy (14).…”

Section: Discussionmentioning

confidence: 99%

Cyclophosphamide-induced disturbance of gonadotropin secretion manifesting testicular damage

Hoorweg-Nijman

Waal

et al. 1992

Acta Endocrinologica

View full text Add to dashboard Cite

Gonadal function was evaluated in 23 men (aged 14.8\p=n-\28.8 years) treated in childhood with cytotoxic drugs for a solid tumour. Group 1 (N = 14) had been treated with non-alkylating drugs only, while group 2 (N=9) received the alkylating drug cyclophosphamide in addition (range 3.8\p=n-\19.5 g/m2).Median age at the start of treatment was 4.6 years (range 0.6\p=n-\16.1) in group 1 and 13.9 years (range 3.7\p=n-\16.9) in group 2. Data of the patients were compared with a reference group consisting of 14 normal men. Almost all patients of both groups showed normal development of puberty; 13 of the 14 men in group 1 showed normal hormonal values. In group 2, basal LH and FSH as well as the LH and FSH responses to GnRH showed higher levels compared to those of a reference group (p<0.001). Correlation analysis showed an evident correlation between the total dose of received cyclophosphamide and the basal FSH level (r=0.78; p=0.002), the FSH response to GnRH (r=0.73; p=0.002) and the LH response to GnRH (r=0.67; p=0.002). There was no correlation between the hormonal

show abstract

Gonadal Function in Children With Nephrosis Treated With Cyclophosphamide

Cited by 33 publications

References 12 publications

Hypogonadism After Childhood Cancer Treatment

Hypogonadism After Childhood Cancer Treatment

The feasibility and efficacy of gonadotropin-releasing hormone agonists for prevention of chemotherapy induced ovarian failure in patient with gynecological malignancies

Cyclophosphamide-induced disturbance of gonadotropin secretion manifesting testicular damage

Contact Info

Product

Resources

About